- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Job Postings
- Events
Page 231
Livongo gives $100m IPO a go
Health management app developer Livongo Health was valued at $800m as of 2018, and a range of corporate investors could exit in the offering.
Jul 2, 2019ConnectM moves into Keen Home
ConnectM Technology has acquired the smart vent maker for an undisclosed sum in a deal that handed an exit to NYU Innovation Fund.
Jul 2, 2019Health Catalyst puts IPO plans in motion
UPMC and Kaiser Permanente are both in line for exits after health data platform developer Health Catalyst filed for a $100m initial public offering.
Jul 1, 2019Karuna kicks its way into public markets
PureTech Health-backed neuropsychiatric drug developer Karuna Therapeutics raised $89.2m in an upsized offering that followed $123m in venture capital.
Jul 1, 2019Illuminate Education coaches FastBridge Learning
FastBridge Learning spun out of University of Minnesota in 2015 and has been picked up by edtech firm Illuminate Education.
Jul 1, 2019BridgeBio crosses over to public markets with $349m
AIG scored an exit as genetic disease and cancer drug developer BridgeBio Pharma floated above its range while increasing the number of shares in its IPO.
Jun 28, 2019Morphic shapes $90m initial public offering
Morphic began trading on the Nasdaq Global Market yesterday after issuing 6 million shares priced at $15 each, providing exits to AbbVie, GSK, Novo, Pfizer, Schrödinger and ShangPharma.
Jun 28, 2019Adaptive Biotechnologies shapes $300m IPO
Shares in Adaptive Biotechnologies, backed by Microsoft, Celgene, Illumina, LabCorp and BD Biosciences, soared more than 100% on its first day of trading.
Jun 28, 2019The RealReal realises IPO plans in $300m offering
Novel Group-backed luxury goods marketplace The RealReal will raise $300m in an initial public offering in which it will float above its range.
Jun 28, 2019Morphic shapes $90m initial public offering
Morphic began trading on the Nasdaq Global Market yesterday after issuing 6 million shares priced at $15 each, providing exits to AbbVie, GSK, Novo, Pfizer, Schrödinger and ShangPharma.
Jun 28, 2019About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


